Life Science Investing Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Life Science Investing Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid, Triggering a $25 Million Milestone Payment
Life Science Investing Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
Life Science Investing Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
